Abstract
We compared the differences in growth inhibition of Mycobacterium bovis by monocytes and neutrophils from human immunodeficiency virus (HIV)–infected
persons (n = 12; mean CD4 count = 451/mm3) and healthy controls (n = 6). Phagocytes from all HIV–infected patients were incubated with or
without exogenous granulocyte-macrophate colony–stimulating factor (GMCSF;
500-1000 U/mL). In two of the HIV-infected patients, phagocytes were incubated with
or without interleukin (IL)-2 or IL-8 (500-1000 U/mL). Compared with that in HIV-infected
patients, the reduction of M. bovis growth at 24 hours was 81% greater among monocytes and 69% greater among neutrophils
from healthy controls (P = .03 and .04, respectively). Among HIV-infected patients, we noted greater mycobacterial
reduction in monocytes (49%, P = .04) and neutrophils (42%, P = .05) from the early-stage patients (mean CD4 count = 760/mm3) compared with that in late-stage patients (mean CD4 count = 172/ mm3). Incubation with GM-CSF, IL-2, or IL-8 did not augment mycobactericidal activity.
These findings suggest that the capacity of neutrophils and monocytes from HIV-infected
patients to inhibit the growth of M. bovis is impaired, and this impairment is more pronounced in later stages of HIV infection.
Keywords:
AIDS (acquired immune deficiency syndrome), GCSF (granulocyte colony–stimulating factor), GI (growth index), GMCSF (granulocyte-macrophage colony–stimulating factor), HIV (human immunodeficiency virus), IL (interleukin), TMP/SMX (trimethoprim sulfamethoxazole)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Recombinant granulocyte-macrophage colony–stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex.J Leukoc Biol. 1990; 48: 67-73
- Cytokines enhance neutrophils from human immunodeficiency virus-negative donors and AIDS patients to inhibit the growth of Mycobacterium avium in vitro.Infect Dis. 1997; 175: 891-900
- Granulocyte-macrophage colony–stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients.Proc Natl Acad Sci U S A. 1988; 85: 2763-2766
- Recombinant granulocyte-macrophage colony–stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model.J Infect Dis. 1994; 169: 575-580
- Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony–stimulating factor.J Pediatr. 1990; 117: 531-540
- Defective monocyte function in acquired immune deficiency syndrome (AIDS).J Clin Immunol. 1985; 5: 21-25
- Depressed neutrophil superoxide production in human immunodeficiency virus infection.J Infect Dis. 1993; 167: 1406-1410
- Reversal of accelerated neutrophil apoptosis and restoration of respiratory burst activity with r-metHuG-CSF (Filgrastim) therapy in patients with AIDS.AIDS. 1999; 13: 427-429
- Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils.J Clin Invest. 1998; 102: 663-670
- Granulocyte-macrophage colony stimulating factor restricts gowth of tubercle bacilli in human macrophages.Immunol Lett. 1990; 24: 203-206
- Neutrophils from AIDS patients treated with granulocyte colony-stimulating factor demonstrate enhanced killing of Mycobacterium avium.J Infect Dis. 1998; 178: 1530-1533
- Killing of Mycobacterium avium by neutrophils and monocytes from AIDS patients treated with recombinant granulocyte-macrophage colony–stimulating factor.J Infect Dis. 1999; 180: 229-233
- Isoniazid preventive therapy in human immunodeficiency virus–infected persons.Arch Intern Med. 1997; 157: 1729-1734
- Monocyte function in the acquired immunodeficiency syndrome.J Clin Invest. 1984; 74: 2121-2128
- Granulocyte-macrophage colony stimulating factor upregulates reduced 5-lipoxygenase metabolism in peripheral blood monocyte and neutrophils in AIDS.Blood. 1999; 94: 3897-3905
- Defective monocyte function in acquired immunodeficiency syndrome (AIDS).J Clin Immunol. 1985; 5: 21-25
- Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor.J Infect Dis. 1998; 177: 914-920
- Effect of stimulation of human macrophages on intracellular survival of Mycobacterium bovis bacillus Calmette-Guerin.Am J Respir Crit Care Med. 1999; 159: 1629-1637
- Tumor necrosis factor and granulocyte-macrophage colony-stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M avium.J Leukoc Biol. 1991; 49: 380-387
- Cytokine use in the management of HIV disease.J Acquir Immune Defic Syndr Hum Retroviral. 1997; 16: S1-S12
Article info
Publication history
Accepted:
November 26,
2002
Received in revised form:
November 4,
2002
Received:
August 8,
2002
Identification
Copyright
© 2003 Elsevier Science Inc. Published by Elsevier Inc. All rights reserved.
